Showing 1 - 20 results of 38 for search 'Zhengping Zhuang', query time: 0.07s
Refine Results
-
1
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism by Christopher S Hong, Chunzhang Yang, Zhengping Zhuang
Published 2016-01-01
Article -
2
Targeting PP2A for cancer therapeutic modulation by Halle Ronk, Jared S. Rosenblum, Timothy Kung, Zhengping Zhuang
Published 2022-10-01
Article -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma by Pashayar P. Lookian, David Zhao, Rogelio Medina, Herui Wang, Jan Zenka, Mark R. Gilbert, Karel Pacak, Zhengping Zhuang
Published 2021-03-01
Article -
11
-
12
TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma by Niranjana Amin, Herui Wang, Qi Song, Manju Bhaskar, Sharda Prasad Yadav, Mark R. Gilbert, Harish Pant, Emeline Tabouret, Zhengping Zhuang
Published 2023-07-01
Article -
13
-
14
Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. by David S Xu, Chunzhang Yang, Martin Proescholdt, Elisabeth Bründl, Alexander Brawanski, Xueping Fang, Cheng S Lee, Robert J Weil, Zhengping Zhuang, Russell R Lonser
Published 2012-01-01
Article -
15
PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation by Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M. Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, Hongyan Tong
Published 2017-06-01
Article -
16
-
17
Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC) by Qi Song, Herui Wang, Dongxian Jiang, Chen Xu, Jing Cui, Qi Zhang, Haixing Wang, Jie Huang, Jieakesu Su, Gen Sheng Wu, Zhengping Zhuang, Yingyong Hou
Published 2021-09-01
Article -
18
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade by Winson S. Ho, Herui Wang, Dominic Maggio, John S. Kovach, Qi Zhang, Qi Song, Francesco M. Marincola, John D. Heiss, Mark R. Gilbert, Rongze Lu, Zhengping Zhuang
Published 2018-05-01
Article -
19
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma by Emeline Tabouret, Herui Wang, Niranjana Amin, Jinkyu Jung, Romain Appay, Jing Cui, Qi Song, Antonio Cardone, Deric M. Park, Mark R. Gilbert, Harish Pant, Zhengping Zhuang
Published 2020-07-01
Article -
20
Corrigendum to “A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation” [Pharmacol. Res. 194 (2023) 106851] by Feiqiong Gao, Qigu Yao, Jiaqi Zhu, Wenyi Chen, Xudong Feng, Bing Feng, Jian Wu, Karel Pacak, Jared Rosenblum, Jiong Yu, Zhengping Zhuang, Hongcui Cao, Lanjuan Li
Published 2024-04-01
Article